Molecular pharmacology · 2013
Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hotta Kentaro, Nashimoto Akihiro, Yasumura Eiji, Suzuki Masafumi, Azuma Motoki, Iizumi Yosuke, Shima Daisuke, Nabeshima Ryusuke, Hiramoto Masaki, Okada Akira, Sakata-Sogawa Kumiko, Tokunaga Makio, Ito Takumi, Ando Hideki, Sakamoto Satoshi, Kabe Yasuaki, Aizawa Shinichi, Imai Takeshi, Yamaguchi Yuki, Watanabe Hajime, Handa Hiroshi
Аннотация
Vesnarinone is a synthetic quinolinone derivative used in the treatment of cardiac failure and cancer. It is also known to cause agranulocytosis as a side effect, which restricts its use, although the mechanism underlying agranulocytosis is not well understood. Here, we show that vesnarinone binds to valosin-containing protein (VCP), which interacts with polyubiquitinated proteins and is essential for the degradation of IκBα to activate nuclear factor (NF)κB. We show that vesnarinone impairs the degradation of IκBα, and that the impairment of the degradation of IκBα is the result of the inhibition of the interaction between VCP and the 26S proteasome by vesnarinone. These results suggest that vesnarinone suppresses NFκB activation by inhibiting the VCP-dependent degradation of polyubiquitinated IκBα, resulting in the suppression of tumor necrosis factor-α mRNA expression.